United Therapeutics Corporation (UTHR)
NASDAQ: UTHR · Real-Time Price · USD
418.58
-7.63 (-1.79%)
Oct 24, 2025, 4:00 PM EDT - Market closed
United Therapeutics Revenue
United Therapeutics had revenue of $798.60M in the quarter ending June 30, 2025, with 11.71% growth. This brings the company's revenue in the last twelve months to $3.08B, up 17.62% year-over-year. In the year 2024, United Therapeutics had annual revenue of $2.88B with 23.63% growth.
Revenue (ttm)
$3.08B
Revenue Growth
+17.62%
P/S Ratio
6.10
Revenue / Employee
$2,358,467
Employees
1,305
Market Cap
18.93B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.88B | 549.90M | 23.63% |
| Dec 31, 2023 | 2.33B | 391.20M | 20.20% |
| Dec 31, 2022 | 1.94B | 250.80M | 14.88% |
| Dec 31, 2021 | 1.69B | 202.20M | 13.63% |
| Dec 31, 2020 | 1.48B | 34.50M | 2.38% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
UTHR News
- 12 days ago - United Therapeutics Corporation to Report Third Quarter 2025 Financial Results Before Market Open on Wednesday, October 29, 2025 - Business Wire
- 14 days ago - United Therapeutics to Feature Clinical Data at the CHEST 2025 Annual Meeting - Business Wire
- 4 weeks ago - United Therapeutics Corporation - Special Call - Seeking Alpha
- 4 weeks ago - United Therapeutics Corporation (UTHR) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 5 weeks ago - United Therapeutics Corporation to Review Data from the Successful TETON-2 Pivotal Study of Nebulized Tyvaso® in Idiopathic Pulmonary Fibrosis - Business Wire
- 5 weeks ago - United Therapeutics Corporation to Present at the Bernstein 2nd Annual Healthcare Forum - Business Wire
- 6 weeks ago - United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the European Respiratory Society Congress - Business Wire
- 6 weeks ago - United Therapeutics Corporation (UTHR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript) - Seeking Alpha